Journal of Clinical Oncology
Research Hotspot & Journal Scope - combination
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).
Kazuhiko Nakagawa · Edward B. Garon · Takashi Seto · Makoto Nishio · Santiago Ponce Aix · Chao-Hua Chiu · Keunchil Park · Silvia Novello · Ernest Nadal · Fumio Imamura · Kiyotaka Yoh · Jin-Yuan Shih · Kwok Hung Au · Denis Moro-Sibilot · Sotaro Enatsu · Annamaria Zimmermann · Bente Frimodt-Moller · Carla M. Visseren Grul · Martin Reck ·
MedicineA phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
Laura Quan Man Chow · Justin F. Gainor · Nehal J. Lakhani · Hyun Cheol Chung · Keun-Wook Lee · Jeeyun Lee · Patricia LoRusso · Yung-Jue Bang · F. Stephen Hodi · Philip Fanning · Yonggang Zhao · Feng Jin · Hong Wan · Jaume Pons · Sophia Randolph · Wells A. Messersmith ·
MedicineCB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
Funda Meric-Bernstam · Richard J. Lee · Bradley Curtis Carthon · Othon Iliopoulos · James W. Mier · Manish R. Patel · Nizar M. Tannir · Taofeek K. Owonikoko · Naomi B. Haas · Martin H. Voss · James J. Harding · Ramaprasad Srinivasan · Geoffrey I. Shapiro · Melinda L. Telli · Pamela N. Munster · Richard D. Carvajal · Yonchu Jenkins · Samuel H. Whiting · Johanna C. Bendell · Todd Michael Bauer ·
MedicinePh1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.
Jyoti Malhotra · Petros Nikolinakos · Ticiana Leal · Jonathan M. Lehman · Daniel Morgensztern · Jyoti D. Patel · John Wrangle · Giuseppe Curigliano · Eric Dansin · Laurent Greillier · Melissa L. Johnson · Neal Ready · Gilles Robinet · Satwant Lally · Shekman Wong · Emin Avsar · Ricardo Valenzuela · Charity D. Scripture · Giovanni Selvaggi · Benjamin Besse ·
MedicinePhase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.
Matthew Reilley · Apostolia Maria Tsimberidou · Sarina Anne Piha-Paul · Timothy A. Yap · Siqing Fu · Aung Naing · Jordi Rodon · Ly M. Nguyen · Casey Ager · Martin Meng · Priyamvada Jayaprakash · Manuel Schmidt · Matthias Baumann · Funda Meric-Bernstam · Michael A. Curran · David S. Hong ·
MedicineSafety and efficacy between antihypertensive classes have been compared, but in-class comparisons of angiotensin II receptor blockers (ARBs) in their fixed-dose combinations (FDC) with a calcium channel blocker (CCB) are lacking in Asia.
This review describes the development of whole-cell (wP) and acellular pertussis (aP) vaccines, which, as DTP combination vaccines, have significantly reduced morbidity and mortality from pertussis, and which currently serve as the building blocks for a variety of vaccines used to immunize all infants worldwide.
Critical attributes of these material combinations require further optimisation before these materials would be competitive in the market place.
Safety and efficacy between antihypertensive classes have been compared, but in-class comparisons of angiotensin II receptor blockers (ARBs) in their fixed-dose combinations (FDC) with a calcium channel blocker (CCB) are lacking in Asia.
PATIENT SAMPLE Overall, 8,718 (ADF/LAMP:1,333/7,485) patients who underwent surgery for cervical OPLL from April 1, 2010 to March 31, 2016 in hospitals using the diagnosis procedure combination were analyzed.
Journal of Clinical Oncology
Research Hotspot
Journal of Clinical Oncology
Journal Scope
